Cargando…
Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer
We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan–Meier estimator and log-rank test wer...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184896/ https://www.ncbi.nlm.nih.gov/pubmed/34099764 http://dx.doi.org/10.1038/s41598-021-90506-x |
_version_ | 1783704671517409280 |
---|---|
author | Hwang, Ki-Tae Kim, Young A. Kim, Jongjin Oh, Hyeon Jeong Park, Jeong Hwan Choi, In Sil Park, Jin Hyun Oh, Sohee Chu, Ajung Lee, Jong Yoon Hwang, Kyu Ri |
author_facet | Hwang, Ki-Tae Kim, Young A. Kim, Jongjin Oh, Hyeon Jeong Park, Jeong Hwan Choi, In Sil Park, Jin Hyun Oh, Sohee Chu, Ajung Lee, Jong Yoon Hwang, Kyu Ri |
author_sort | Hwang, Ki-Tae |
collection | PubMed |
description | We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan–Meier estimator and log-rank test were used for survival analyses. The Cox proportional hazards model was used to calculate hazard ratio (HR) and the 95% confidence interval (CI) of survival analyses. BCL1 expression revealed no impact on survival. The high BCL2 group showed superior disease-free survival compared with the low BCL2 group (p = 0.002), especially regarding local recurrence-free survival (p = 0.045) and systemic recurrence-free survival (p = 0.002). BCL2 expression was a significant prognostic factor by univariable analysis (HR, 0.528; 95% CI, 0.353–0.790; p = 0.002) and by multivariable analysis (HR, 0.547; 95% CI, 0.362–0.826; p = 0.004). High BCL2 expression was associated with higher disease-free survival in the hormone receptor (HRc)-positive and human epidermal growth factor receptor 2 (HER2)-negative (HRc(+)/HER2(−)) subtype only (p = 0.002). The high BCL2 group was associated with positive estrogen receptor (ER), positive progesterone receptor (PR), low histologic grade, and age ≤ 50 years. BCL1 expression had no prognostic impact, but BCL2 expression was a significant independent prognostic factor. High BCL2 expression was associated with higher disease-free survival, especially regarding local recurrence and systemic recurrence. The prognostic effect of BCL2 expression was effective only in the HRc(+)/HER2(−) subtype. Favorable clinicopathologic features and a strong association with the ER/PR status could partly explain the superior prognosis of the high BCL2 group. BCL2 expression could be utilized to assess the prognosis of breast cancer patients in clinical settings. |
format | Online Article Text |
id | pubmed-8184896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81848962021-06-08 Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer Hwang, Ki-Tae Kim, Young A. Kim, Jongjin Oh, Hyeon Jeong Park, Jeong Hwan Choi, In Sil Park, Jin Hyun Oh, Sohee Chu, Ajung Lee, Jong Yoon Hwang, Kyu Ri Sci Rep Article We investigated the prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer patients. BCL1 and BCL2 expression statuses were assessed by immunohistochemistry using tissue microarrays from 393 breast cancer patients. The Kaplan–Meier estimator and log-rank test were used for survival analyses. The Cox proportional hazards model was used to calculate hazard ratio (HR) and the 95% confidence interval (CI) of survival analyses. BCL1 expression revealed no impact on survival. The high BCL2 group showed superior disease-free survival compared with the low BCL2 group (p = 0.002), especially regarding local recurrence-free survival (p = 0.045) and systemic recurrence-free survival (p = 0.002). BCL2 expression was a significant prognostic factor by univariable analysis (HR, 0.528; 95% CI, 0.353–0.790; p = 0.002) and by multivariable analysis (HR, 0.547; 95% CI, 0.362–0.826; p = 0.004). High BCL2 expression was associated with higher disease-free survival in the hormone receptor (HRc)-positive and human epidermal growth factor receptor 2 (HER2)-negative (HRc(+)/HER2(−)) subtype only (p = 0.002). The high BCL2 group was associated with positive estrogen receptor (ER), positive progesterone receptor (PR), low histologic grade, and age ≤ 50 years. BCL1 expression had no prognostic impact, but BCL2 expression was a significant independent prognostic factor. High BCL2 expression was associated with higher disease-free survival, especially regarding local recurrence and systemic recurrence. The prognostic effect of BCL2 expression was effective only in the HRc(+)/HER2(−) subtype. Favorable clinicopathologic features and a strong association with the ER/PR status could partly explain the superior prognosis of the high BCL2 group. BCL2 expression could be utilized to assess the prognosis of breast cancer patients in clinical settings. Nature Publishing Group UK 2021-06-07 /pmc/articles/PMC8184896/ /pubmed/34099764 http://dx.doi.org/10.1038/s41598-021-90506-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Hwang, Ki-Tae Kim, Young A. Kim, Jongjin Oh, Hyeon Jeong Park, Jeong Hwan Choi, In Sil Park, Jin Hyun Oh, Sohee Chu, Ajung Lee, Jong Yoon Hwang, Kyu Ri Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer |
title | Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer |
title_full | Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer |
title_fullStr | Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer |
title_full_unstemmed | Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer |
title_short | Prognostic influences of BCL1 and BCL2 expression on disease-free survival in breast cancer |
title_sort | prognostic influences of bcl1 and bcl2 expression on disease-free survival in breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184896/ https://www.ncbi.nlm.nih.gov/pubmed/34099764 http://dx.doi.org/10.1038/s41598-021-90506-x |
work_keys_str_mv | AT hwangkitae prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT kimyounga prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT kimjongjin prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT ohhyeonjeong prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT parkjeonghwan prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT choiinsil prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT parkjinhyun prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT ohsohee prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT chuajung prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT leejongyoon prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer AT hwangkyuri prognosticinfluencesofbcl1andbcl2expressionondiseasefreesurvivalinbreastcancer |